Business Context and Reporting Period
Company: Embraer S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fourth Quarter (4Q) and Full Year ended December 31, 2020.
Context: The company operates in Commercial Aviation, Executive Jets, Defense & Security, and Services & Support. Operations were significantly impacted by the COVID-19 pandemic, resulting in reduced commercial air travel and lower aircraft deliveries. The company delivered 28 commercial jets and 43 executive jets in 4Q20, totaling 44 commercial and 86 executive jets for the full year 2020.
Key Financial Metrics
| Metric (in millions USD) | 4Q20 | Full Year 2020 | Full Year 2019 |
|---|---|---|---|
| Revenue | 1,841.4 | 3,771.1 | 5,462.6 |
| EBIT (Reported) | 103.6 | (323.4) | (77.0) |
| Adjusted EBIT | 76.6 | (100.5) | (5.4) |
| Adjusted EBITDA | 145.6 | 82.1 | 181.9 |
| Net Loss (Attributable to Shareholders) | (3.3) | (731.9) | (322.3) |
| Adjusted Net Loss | (12.5) | (463.7) | (217.5) |
| Adjusted Free Cash Flow | 725.1 | (990.2) | (181.8) |
| Total Cash Position | 2,752.3 | 2,752.3 | 2,779.9 |
| Net Debt | (1,695.7) | (1,695.7) | (612.4) |
| Firm Order Backlog | 14.4 billion | 14.4 billion | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Full-year 2020 revenue fell 31.0% year-over-year (YoY) to $3.77 billion, driven by a 51% drop in commercial jet deliveries and a 21% drop in executive jet deliveries due to the pandemic. 4Q20 revenue declined 11.7% YoY.
- Profitability: Reported EBIT for 2020 was a loss of $323.4 million compared to a loss of $77.0 million in 2019. However, 4Q20 showed a significant recovery with reported EBIT of $103.6 million (margin 5.6%) compared to a loss of $67.6 million in 4Q19.
- Cash Flow: The company generated $725.1 million in adjusted free cash flow in 4Q20, a stark contrast to the full-year usage of $990.2 million. This improvement was driven by high delivery volumes in the quarter and working capital releases.
- Debt Position: Net debt increased to $1.696 billion at year-end 2020 from $612.4 million in 2019, though it improved sequentially from $2.365 billion in 3Q20.
- Segment Performance: Defense & Security revenue grew 68.1% in 4Q20 YoY, offsetting declines in Commercial Aviation (-24.7%) and Services & Support (-29.6%).
Guidance, Outlook, and Risks
- Guidance: Due to continued uncertainty related to the COVID-19 pandemic, Embraer has decided not to publish 2021 financial and delivery guidance at this time.
- Outlook: Management noted a significant recovery in 4Q20 operating results, with 55% of the year's commercial and executive jet deliveries occurring in the fourth quarter. The company expects the delivery of 4,420 new jets (up to 150 seats) and 1,080 new turboprops by 2029 based on its 2020 Commercial Market Outlook.
- Risks and Contingencies:
- Pandemic Impact: Ongoing effects on commercial air travel and customer creditworthiness remain primary risks.
- Special Items: 2020 results included $223.0 million in net negative special items, including restructuring expenses ($69.2 million) and additional provisions for expected credit losses ($52.6 million).
- Exchange Rate: Approximately 10% of net revenues are in Reais while 20% of costs are in Reais, creating cash flow exposure. The company has hedged approximately half of this exposure for 2021.
Investor Verification Checklist
- Delivery Volumes: Verify the 4Q20 delivery count (28 commercial, 43 executive) against the backlog of $14.4 billion to assess near-term revenue visibility.
- Working Capital Trends: Monitor the reduction in inventories ($768.9 million drop in 4Q20) and contract liabilities to ensure cash flow sustainability.
- Credit Provisions: Review the $52.6 million provision for expected credit losses in 2020 and the $9.9 million reversal in 4Q20 to gauge customer financial health.
- Debt Maturity: Confirm the average loan maturity of 4.4 years and the cost of debt (5.03% for USD loans) to evaluate refinancing risks.
- Non-GAAP Reconciliations: Scrutinize the adjustments made to reach Adjusted EBIT and Adjusted Net Income, specifically the treatment of restructuring and impairment reversals.